DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Ubicación actual:
>
> This Story


Conexión o Registro to rate this News Story
Forward Printable StoryPrint Comment

 

 

Molecular Imaging Homepage

New PET imaging method may yield benefits over FDG for detecting certain cancers Gallium-68-labeled FAPI tracer yields promising results

Dr. David Wong Professor recognized for contributions to PET and Theranostics

SVSR unveils Siemens Horizon PET/CT trailer Putting a small and powerful scanner on a coach

Philips to manage medical imaging equipment for Aussie providers for 20 years First-of-its-kind partnership in Australia and ASEAN Pacific region

Under AMG, Piramal Imaging changes name to Life Molecular Imaging LMI is being run within the Alliance Medical Molecular Imaging division

RadioMedix Inc. and Curium to develop and commercialize PET agent 64Cu-Dotatate for use in suspected neuroendocrine tumors

Dr. Sanjiv Gambhir Stanford’s chair of radiology wins Cassen Prize

Researchers undertake 'largest brain study' using 60,000 SPECT images Evaluate accelerated brain aging in scans

SNMMI proposes solutions to Ga-68 generator shortage Combating waiting periods of between 14 and 18 months

Tc-99m generator production resumes in Australia Follows month and a half shutdown due to conveyor belt issue

NOPR and others urge CMS to reconsider NaF PET coverage

por John R. Fischer , Staff Reporter
Patients prescribed a PET scan with 18F-sodium fluoride will still have to dip into their own pockets following the Centers for Medicare and Medicaid Services’ rejection of a request to reconsider covering the contrast agent.

Written and signed by the National Oncologic PET Registry (NOPR) working group, the request called for CMS to reevaluate its National Coverage Determination for NaF PET on the basis that the substance provided more appropriate forms of care to patients.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



"The NOPR data clearly show that use of NaF PET led to more appropriate care for many cancer patients. We urge CMS to reconsider coverage for these potentially lifesaving and life-improving exams," NOPR principal investigator Dr. Bruce Hillner, said in a statement.

Following its closure of NOPR in December 2017, CMS chose to restrict reimbursements for the use of NAF PET in detecting cancerous bone metastases, asserting that such scans are “not reasonable and necessary to diagnose or treat an illness or injury or to improve the functioning of a malformed body member,” in a memo.

The agency agreed to continue reimbursing NaF-18 PET with evidence development programs for 24 months as it awaited the publication of evidence in The Journal of Nuclear Medicine, the findings of which ultimately supported the notion that the contrast agent offers more appropriate palliative and curative care in patient management.

The peer-review journal also approved of its use in 2016 as part of a pilot study that associated it with better clinical outcomes and patient survival.

Backing the NOPR proposal is the Society of Nuclear Medicine and Molecular Imaging, which made its own recommendations to CMS about the agent in March, along with The World Molecular Imaging Society (WMIS) and the American College of Radiology.

All three collaborated with CMS and NOPR upon its launch in 2011 to collect clinical utility data supporting the use of NaF-18 PET. NOPR used applied these findings to more than 65,000 scans it performed on Medicare beneficiaries in that time.

Despite the recommendations and evidence, CMS declined the NOPR request, citing the information provided as insufficient.

"Many seniors may ultimately receive care that is not as effective or helpful as it could be if CMS does not reconsider Medicare coverage for NaF PET,” NOPR co-chair Dr. Anthony Shields said in a statement. “This is a step backward in care for these patients. We urge CMS to reconsider coverage so that these seniors can have access to care that can better help them.”

WMIS, ACR and SNMMI will continue to collaborate with CMS to establish Medicare coverage and access for patients to NaF PET.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente su conciencia de marca
Subastas + ventas Privadas
Consigue el mejor precio
Comprar Equipo/Piezas
Encuentra El Precio Más Bajo
Noticias diarias
Lee las últimas noticias
Directorio
Examina todos los usuarios DOTmed
Ética en DOTmed
Ver nuestro programa de ética
El oro parte programa del vendedor
Recibir las solicitudes de PH
Programa de distribuidor con servicio gold
Recibe solicitudes
Proveedores de atención de salud
Ver todos los HCP (abreviatura de asistencia médica) Herramientas
Trabajos/Entrenamiento
Encontrar/rellenar un trabajo
Parts Hunter +EasyPay
Obtener presupuestos para piezas
Certificado recientemente
Ver usuarios certificados recientemente
Recientemente clasificado
Ver usuarios certificados recientemente
Central de alquiler
Alquila equipos por menos
Vende equipos/piezas
Obtén más dinero
Mantenga el foro de los técnicos
Buscar ayuda y asesoramiento
Petición sencilla de propuestas
Obtén presupuestos para equipos
Feria comercial virtual
Encuentra servicio para el equipo
El acceso y el uso de este sitio está conforme a los términos y a las condiciones de nuestro AVISO LEGAL & AVISO DE LA AISLAMIENTO
Característica de y propietario DOTmeda .com, inc. Copyright ©2001-2018 DOTmed.com, Inc.
TODOS LOS DERECHOS RESERVADOS